Head-to-head comparison of [^68Ga]Ga-P16-093 and 2-[^18F]FDG PET/CT in patients with clear cell renal cell carcinoma: a pilot study

[1]  F. Zhou,et al.  Special issue “The advance of solid tumor research in China”: 68Ga‐PSMA‐11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma , 2022, International journal of cancer.

[2]  M. Daube-Witherspoon,et al.  Preliminary Evaluation of 68Ga-P16-093, a PET Radiotracer Targeting Prostate-Specific Membrane Antigen in Prostate Cancer , 2022, Molecular Imaging and Biology.

[3]  Zhengyu Jin,et al.  Utilisation of virtual non-contrast images and virtual mono-energetic images acquired from dual-layer spectral CT for renal cell carcinoma: image quality and radiation dose , 2022, Insights into Imaging.

[4]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[5]  H. Kung,et al.  Head-to-head comparison of [68 Ga]Ga-P16-093 and [68 Ga]Ga-PSMA-617 in dynamic PET/CT evaluation of the same group of recurrent prostate cancer patients , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  Ho-Yyoung Lee,et al.  Role of F-18 FDG PET/CT in the follow-up of asymptomatic renal cell carcinoma patients for postoperative surveillance: based on conditional survival analysis , 2021, Journal of Cancer Research and Clinical Oncology.

[7]  Y. Xiong,et al.  Noninvasive evaluation of tumor immune microenvironment in patients with clear cell renal cell carcinoma using metabolic parameter from preoperative 2-[18F]FDG PET/CT , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  G. Carlucci,et al.  68Ga-PSMA-11 NDA Approval: A Novel and Successful Academic Partnership , 2020, The Journal of Nuclear Medicine.

[9]  A. Nadu,et al.  Dynamic 68Ga-PSMA-11 PET/CT for the Primary Evaluation of Localized Renal Mass: A Prospective Study , 2020, The Journal of Nuclear Medicine.

[10]  Xueqi Chen,et al.  2-[18F]FDG PET/CT parameters associated with WHO/ISUP grade in clear cell renal cell carcinoma , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  Jiong Shi,et al.  Comprehensive evaluation of 68Ga-PSMA-11 PET/CT parameters for discriminating pathological characteristics in primary clear-cell renal cell carcinoma , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Janet S. Reddin,et al.  Biodistribution, dosimetry, and temporal signal-to-noise ratio analyses of normal and cancer uptake of [68Ga]Ga-P15-041, a gallium-68 labeled bisphosphonate, from first-in-human studies. , 2020, Nuclear medicine and biology.

[13]  G. Gueglio,et al.  Renal fossa recurrence after radical nephrectomy: Current management, and oncological outcomes. , 2019, Urologic oncology.

[14]  Renzhi Wang,et al.  Fusion Radiomics Features from Conventional MRI Predict MGMT Promoter Methylation Status in Lower Grade Gliomas. , 2019, European journal of radiology.

[15]  G. Hutchins,et al.  [68Ga]Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for Detection of Cancer: Initial Evaluation and Comparison with [68Ga]Ga-PSMA-11 in Prostate Cancer Patients Presenting with Biochemical Recurrence , 2019, Molecular Imaging and Biology.

[16]  J. Yaxley,et al.  The use of 68Ga-PET/CT PSMA in the staging of primary and suspected recurrent renal cell carcinoma , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  W. Oyen,et al.  Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  Huadan Xue,et al.  Can quantitative CT texture analysis be used to differentiate subtypes of renal cell carcinoma? , 2019, Clinical radiology.

[19]  A. Buck,et al.  68Ga-PSMA I&T PET/CT for primary staging of prostate cancer , 2019, Nuklearmedizin.

[20]  M. van Engeland,et al.  Epigenetics in renal cell cancer: mechanisms and clinical applications , 2018, Nature Reviews Urology.

[21]  G. Kristiansen,et al.  Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role , 2018, The Journal of urology.

[22]  H. Kung,et al.  Synthesis and evaluation of a novel urea-based 68Ga-complex for imaging PSMA binding in tumor. , 2017, Nuclear medicine and biology.

[23]  W. Brenner,et al.  Immunohistochemical Validation of PSMA Expression Measured by 68Ga-PSMA PET/CT in Primary Prostate Cancer , 2017, The Journal of Nuclear Medicine.

[24]  V. Goh,et al.  Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F–Fluorodeoxyglucose (18F–FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study , 2017, BMC Cancer.

[25]  J. Preston,et al.  Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour , 2016, EJNMMI Research.

[26]  Yiyan Liu.  The Place of FDG PET/CT in Renal Cell Carcinoma: Value and Limitations , 2016, Front. Oncol..

[27]  Tim Holland-Letz,et al.  The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions , 2015, The Journal of Nuclear Medicine.

[28]  P. Russo,et al.  Expression of prostate-specific membrane antigen in renal cortical tumors , 2008, Modern Pathology.

[29]  I. Buvat,et al.  Partial-Volume Effect in PET Tumor Imaging* , 2007, Journal of Nuclear Medicine.

[30]  H. Bensadoun,et al.  Efficiency of [18F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  S. Yasuda,et al.  Significance of 18F‐fluorodeoxyglucose positron emission tomography (FDG‐PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT‐1) expression in the cancer , 2002, International journal of urology : official journal of the Japanese Urological Association.

[32]  D. Bostwick,et al.  Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. , 1998, Urology.

[33]  M. Pomper,et al.  Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT , 2019, Annals of Nuclear Medicine.

[34]  G. Antoch,et al.  Diagnostic potential of PET/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience , 2016, European Journal of Nuclear Medicine and Molecular Imaging.